Regulation of cAMP responses by the G12/13 pathway converges on adenylyl cyclase VII by Jiang, Lily I. et al.
Regulation of cAMP Responses by the G12/13 Pathway Converges on Adenylyl 
Cyclase VII* 
 
Lily I. Jiang‡1, Julie Collins‡, Richard Davis‡, Iain D. Fraser§, and Paul C. Sternweis‡2 
 
From the Alliance for Cellular Signaling: ‡ Department of Pharmacology, UT Southwestern Medical 
Center, 5323 Harry Hines Boulevard, Dallas, TX 75390.  § Division of Biology, Caltech, MC 147-75, 
1200 E. California Boulevard, Pasadena, CA 91125. 
 
Running title: Isoform specific regulation of AC7 by the G12/13 pathway 
 
1Address correspondence to: Lily I. Jiang, UT Southwestern Medical Center, 5323 Harry Hines Blvd, 
Dallas, TX 75390.  Tel: (214)-645-6105 ; Fax: (214)-645-6118 ; E-mail: lily.jiang@utsouthwestern.edu. 
2Address correspondence to: Paul C. Sternweis, UT Southwestern Medical Center, 5323 Harry Hines 
Blvd, Dallas, TX 75390.  Tel: (214)-645-6149; Fax: (214)-645-6151; E-mail: 
paul.sternweis@utsouthwestern.edu 
 
Regulation of intracellular cyclic adenosine 
3’, 5’-monophosphate (cAMP) by multiple 
pathways enables differential function of this 
ubiquitous second messenger in a context 
dependent manner.  Modulation of Gs-
stimulated intracellular cAMP has long been 
known to be modulated by the Gi and Gq/Ca2+ 
pathways.  Recently, the G13 pathway was also 
shown to facilitate cAMP responses in murine 
macrophage cells.  We report here that this 
synergistic regulation of cAMP synthesis by the 
Gs and G13 pathways is mediated by a specific 
isoform of adenylyl cyclase, AC7.  Furthermore, 
this signaling paradigm exists in several 
hematopoietic lineages and can be recapitulated 
by exogenous expression of AC7 in HEK 293 
cells.  Mechanistic characterization of this 
synergistic interaction indicates that it occurs 
downstream of receptor activation and it can be 
mediated by the α subunit of either G12 or G13.  
Our results demonstrate that AC7 is a specific 
downstream effector of the G12/13 pathway. 
 
 The second messenger, cyclic adenosine 3’, 
5’-monophosphate (cAMP), is ubiquitously 
utilized by many cell types to regulate a variety of 
fundamental physiological functions (1-6).  This 
precise control of various cellular functions and 
subsequent physiological processes requires that 
regulation of intracellular cAMP concentration 
occur in a cell type dependent manner (7,8).  
Specificity is achieved at multiple levels including 
synthesis, degradation and selective response to 
extracellular stimuli (7-11).  Key mechanisms for 
differential regulation in the synthetic pathway 
occur at the level of adenylyl cyclase (AC)3 
enzymes. 
Synthesis of cAMP by membrane-bound AC 
is primarily regulated by the heterotrimeric Gs 
protein and its modulation by ligand binding to G-
protein coupled receptors (GPCR) (12,13).  There 
are nine membrane bound mammalian ACs which 
can be divided into four subgroups based on their 
sequence similarities and regulatory properties 
(11,14,15).  AC1, AC3, and AC8 can be 
stimulated by Ca2+/calmodulin upon elevation of 
intracellular free Ca2+ through voltage-gated Ca2+ 
channels or capacitative entry.  The activities of 
AC2, AC4, and AC7 isoforms are stimulated by 
the βγ subunits of G proteins.  In this case, 
regulation requires coordinate stimulation with Gs 
and Gβγ acts synergistically to enhance the 
catalytic activities of this class of ACs.  AC5 and 
AC6 are generally inhibited by a variety of 
pathways, including Ca2+ and Gαi.  The AC9 
isotype is unique among the membrane ACs in 
that it is insensitive to activation by the diterpene, 
forskolin.   
The complex regulation of AC activities 
makes them ideal for translating inputs from 
multiple pathways into integrated cAMP responses.  
Regulation of AC activities by the Gi and Gq/Ca2+ 
pathways has been well studied both in vitro and 
in vivo (11,14,15).  Recently, regulation of cAMP 
responses by the G13 pathway was also reported 
(16), thereby establishing that cAMP can be 
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regulated by all major groups of heterotrimeric G 
proteins.  In the latter study, a genetically 
engineered BRET sensor for cAMP, CAMYEL, 
was used to measure transient changes in 
intracellular cAMP in real time and in greater 
detail in living cells. It was shown that activation 
of the G13 pathway greatly enhanced Gs-stimulated 
cAMP responses in murine macrophage cells and 
that this synergistic interaction was transient and 
occurred at the level of cAMP synthesis, not its 
degradation.   
Here we report the identification of a specific 
AC isoform, AC7, as the key integrator that 
mediates the regulation of cAMP responses from 
the G13 pathway. The extension of this observation 
to both human erythroleukemia cells (HEL) and 
primary macrophages derived from bone marrow 
demonstrate that this regulation is a conserved 
signaling motif utilized by several hematopoietic 
lineages.  We further show that regulation of AC7 
activity is mediated by the α subunit of G13 and 
both Gα12 and Gα13 are capable of mediating the 
synergistic effect on AC7 activity.  However, the 
constitutively active proteins, Gα13QL or Gα12QL, 
act as dominant negative proteins with respect to 
cAMP regulation.  These results suggest that AC7 
may be a direct or indirect downstream effector of 
the G12/13 pathway.   
 
EXPERIMENTAL PROCEDURES 
 
Reagents.   Isoproterenol, prostaglandin E1, 
complement C5a, uridine 5’-diphosphate, 
thrombin, and forskolin were obtained from Sigma. 
Sphingosine-1-phosphate (Avanti Polar Lipids), 
doxycyclin (Clontech), pertussis toxin and cholera 
toxin (List Biological) were purchased from the 
sources indicated. 
Cell culture and generation of stable cell lines 
via retroviral transfection.  Protocols for culturing 
RAW 264.7 cells and for retroviral infection were 
described previously (16).  The HEL cell line was 
obtained from ATCC and cultured in RPMI 1640 
supplemented with 10% FBS, 2 mM L-glutamine, 
and 20 mM NaHEPES, pH 7.4.  HEK 293 cells 
were cultured in DMEM supplemented with 10% 
FBS, 2 mM L-glutamine, and 20 mM NaHEPES, 
pH 7.4.  Transfection with DNA was carried out 
using LipoFectamine 2000 (Invitrogen) according 
to the manufacturer’s protocol.  Retrovirus was 
made with the Phoenix Amphotropic packaging 
cell line (Orbigen).  Infection of cells was initiated 
by application of virus-containing supernatant 
harvested from the packaging cell line and 6 µg/ml 
polybrene on top of the targeted cells and spinning 
at 1,200 x g at 32 ºC for 2 hours.  Cells were then 
cultured with the viral supernatant for one day at 
32 ºC.  The viral supernatant was then removed 
and cells were cultured with fresh medium 
containing 100 µg/ml to 500 µg/ml hygromycin 
(depending on cell line) at 37 ºC for selection, 
expansion and maintenance. The transduction 
efficiency of this method ranges from 50-80% 
based on the number of cells surviving selection. 
Isolation of BMDM and retroviral infection.  
AC7 knockout mice were purchased from the 
Jackson Laboratory and bred by intercrossing 
heterozygous males and females. All experimental 
procedures involving animals in this study were 
reviewed and approved by the Institutional Animal 
Care and Research Advisory Committee at 
University of Texas Southwestern Medical Center.  
Bone marrow derived primary macrophages were 
isolated from mouse femurs and cultured as 
described (17).  Briefly, 6-8 week old mice were 
sacrificed and femurs were isolated.  Bone marrow 
cells were flushed out of the femur bones and red 
blood cells were lysed.  The remaining cells were 
cultured on non-TC coated dishes in DMEM 
supplemented with macrophage colony-
stimulating factor provided by addition of 10% 
conditioned medium from CMG14-12 cells 
(kindly provided by Dr. T. Roach), 55 µM β-
mercaptoethanol, 10% FBS, 2 mM L-glutamine, 
20 mM NaHEPES, pH 7.4, 100 U/ml penicillin, 
and 100 µg/ml streptomycin.  PlatE cells (kindly 
provided by Dr. T. Roach) were transfected with 
retrovirus constructs using Fugene HD (Roche) to 
produce retrovirus for infection of BMDM.  A 1:1 
mixture of viral supernatant and BMDM growth 
medium supplemented with 8 µg/ml polybrene 
was added on top of BMDM cells on the 2nd day 
after BMDM isolation.  After culturing the cells at 
32 ºC for 1 day the media was supplemented with 
fresh viral supernatant for another day.  Infected 
BMDMs were expanded for 4 days and briefly 
selected with 50 µg/ml hygromycin before being 
used for BRET assays.  The transduction 
efficiency of this method is about 20-40% based 
on the number of BMDMs that survived selection. 
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Assay of BRET in live cells.  Adherent cells 
were plated in 96-well solid-white tissue culture 
plates (Greiner) at a density of 40,000-60,000 cells 
per well the day before assays.  Suspension cells 
were plated on the day of assay at 100,000 cells 
per well.  Cells were serum starved in Hank’s-
balanced salt solution, pH 7.4, for 1 hour before 
treatments.  The BRET assay was carried out with 
a POLARstar Optima plate reader from BMG 
LabTech.  Emission signals from Renilla 
luciferase and YFP were measured simultaneously 
using a BRET1 filter set (475-30/535-30).  Cells in 
each well were assayed in 80 µl of Hank’s-
balanced salt solution with 2 µM coelenterazine-h 
and stimulations were initiated by injection of 20 
µl of 5x ligand.  Calculation of cAMP 
concentration was done as described before (16). 
Gene knockdown by RNAi.  siRNA oligomers 
targeting mouse AC7, mouse AC9, human AC7, 
and human Gα13 were SMARTPool products 
purchased from Dharmacon.  They were used 
either as a pool of 4 different oligos (designated as 
-P) or as individual oligos (letter designation other 
than -P).  Cells were transfected with 200 nM 
siRNA using HiPerFect reagent (Qiagen).  Cells 
were plated into 96-well tissue culture plates at 24 
hours post-transfection and assayed at 48 hours 
post-transfection.  Mouse AC2 and AC3 were 
knocked down using stable expression of shRNA 
in the pFBneo vector (Stratagene) (18).  The 
sequences for the AC2-D and AC3-A oligomers 
are 5’-CCG GAT CAA GCT GGA ATT TGA A-
3’ and 5’-TCC GGG TCA TCA CCA AGA 
TCAA-3’, respectively.   
DNA constructs and inducible gene expression.  
Mouse Gα13QL cDNA was a kind gift from Dr. 
William Singer.  Human Gα12 and Gα12QL 
cDNAs were obtained from cdna.org.  All cDNAs 
were cloned into the pSLIKneo construct where 
gene expression is driven by an inducible TRE 
promoter (19).  Lentivirus was produced by co-
transfection of 4 plasmids into 293T cells and 
concentrated viral supernatant was used to infect 
RAW cells as described (19).  Stable RAW cell 
lines were established using medium containing 
500 µg/ml G418.  Gene expression was induced 
by culturing the cells with medium containing 0.5 
µg/ml doxycyclin for 1 day.   
Quantification of gene and protein expression.  
Samples were taken for analysis by western blot or 
qRT-PCR to assess the expression level of protein 
or mRNA, respectively.  Antibodies used in the 
experiments include anti-Gα13 (B-860) (20), anti-
Gα12 (Santa Cruz Biotechnology), anti-Flag 
(Sigma), anti-V5 (Invitrogen), anti-His (R&D 
systems), and anti-myc (Cell Signaling 
Technology).  Primers used for qRT-PCR are: 
mAC2 (F) 5’- TAC TGC CAA AAA CGT CCA 
TCC-3’ and (R) 5’- GCA TTG CAA AAG CTG 
TCC AG-3’; mAC3 (F) 5’-CAA TGG CAC TGA 
CAG CAT GC -3’ and (R) 5’-CGT GGC GCG 
AGA AGT AGT AAA -3’; mAC7 (F) 5’- GCC 
TTC GAC TGC TGA ATG AGA-3’ and (R) 5’-
GCC ATG TAG GTG CTG CCA AT -3’; mAC9 
(F) 5’-GCT CAG CTC CTG GAT GAG GT -3’ 
and (R) 5’- ACA TCA CAA TGG AAC TGT 
CCT GAC-3’; hAC7 (F) 5’-CGC GAG CAG 
CAA GAC AAG A -3’ and (R) 5’-AGG CTC 
ATC CTC AGG AAG ACC -3’.  The qRT-PCR 
reactions were done with an ABI 7500 Real-Time 
PCR system from Applied Biosystems.  Primers 
used for genotyping AC7 wild type and knockout 
alleles are wild type 5’-GTT CTC ACC ATG 
TGG GGT TAG TAT G -3’, knockout 5’- GGG 
TGG GAT TAG ATA AAT GCC TGC TCT-3’, 
and 5’-ACA AGC TGG GGC ATA TAG CAG 
TTAG-3’ (http://www.informatics.jax.org/external 
/ko/deltagen/1519.html).  
EIA assay for cAMP.  Cells were plated on 96-
well tissue culture plates and cultured for one day.  
Prior to treatments, cells were cultured in serum-
free medium for 1 hour.  Ligands (10x) were then 
added to stimulate the cells.  After the addition of 
ligands, reactions were stopped at the indicated 
times by removal of medium and cell lysis with 
65% ethanol.  Cell lysates were then dried and 
assayed using the cAMP Biotrak EIA kit 
(Amersham Biosciences). 
Assay of activated Rho.  Cells (1x106) were 
plated on 60 mm tissue culture dishes one day 
prior to the assay.  On the day of assay, cells were 
cultured in serum-free medium for 1 hour.  
Ligands were then added to stimulate the cells.  
Reactions were stopped after 1 minute of 
stimulation by rapid removal of medium and 
placement on ice; the cells were immediately 
washed with ice-cold 1xPBS and lysed with 110 
µl lysis buffer.  Cell lysates were cleared by brief 
centrifugation and assayed using the G-LISA 
RhoA activation assay kit (Cytoskeleton Inc.). 
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RESULTS 
 
In the murine macrophage like cell line, RAW 
264.7, activation of β-adrenergic receptors and the 
Gs pathway with isoproterenol (ISO) increases 
concentrations of intracellular cAMP.  Addition of 
sphingosine-1-phosphate (S1P) either 
simultaneously or sequentially greatly enhances 
this cAMP response induced by ISO.  We have 
shown previously that this synergistic effect is 
mediated by the S1P2 receptor and the 
heterotrimeric G protein, G13 (16).  Several 
experiments also indicate that this interaction 
occurs at the level of cAMP synthesis and 
downstream of the receptors.  Therefore, a likely 
hypothesis is that this synergism between the Gs 
and G13 pathways occurs through regulation of a 
specific isoform of adenylyl cyclase. 
 
Knockdown of the AC7 isoform of adenylyl cyclase 
attenuates the effect of G13 on cAMP.  RAW 264.7 
cells express four isoforms of transmembrane AC 
according to RT-PCR: AC2, AC3, AC7, and AC9.  
To determine if the regulation of cAMP response 
by the G13 pathway is mediated by a specific 
isoform of AC, RNAi was used to knockdown 
each of the four ACs individually.  Based on 
quantitative RT-PCR, mRNA for each isoform 
could be specifically knocked down by at least 
60% with essentially no effect on other isoforms 
(Fig. 1A).  Knockdown of AC2, AC3, or AC9 did 
not produce a significant effect on cAMP 
responses to either ISO or S1P.  However, 
knockdown of AC7 greatly reduced the synergistic 
effect of S1P on intracellular cAMP (Fig. 1B).  
When S1P was added following addition of ISO, 
the response (second peak) in cells transfected 
with siRNAs targeting AC7 was reduced to less 
than 20% of control cells.  The specificity of the 
RNAi effect was verified by using several siRNAs 
and an shRNA targeting different regions of the 
AC7 gene (Supplementary Fig. 1) and was 
supported by the fact that AC7-specific RNAi 
oligos did not affect the expression of other ACs 
in RAW cells.   
The rise in cAMP caused by ISO alone was 
only slightly reduced in cells with reduced AC7 
and was not affected by the knockdown of other 
AC isoforms.  This is likely due to the redundancy 
of the several AC isoforms, which suggests that 
stimulated Gs in these cells activates multiple AC 
isoforms to raise intracellular cAMP while the 
regulation from the G13 pathway is largely 
dependent on a single isoform, AC7. 
 
The effect of thrombin on Gs-stimulated cAMP 
response in HEL cells is mediated by G13 and AC7.  
Is the regulation of Gs-stimulated cAMP responses 
by the G13 pathway via AC7 a conserved signaling 
motif utilized by other cell lines? We tested this 
possibility by examining the cAMP responses in 
cultured human erythroleukemia cells (HEL).  It 
has been reported that thrombin greatly enhances 
the Gs-stimulated cAMP response in HEL cells 
(21,22).  While it was not clear how thrombin 
effects this regulation it did not seem to be 
mediated by the Gi or the Gq/Ca2+ pathways.  A 
second observation of interest was the original 
cloning of AC7 cDNA from HEL cells (23), an 
indication that this isoform of AC was highly 
expressed in these cells.   
For real-time measurement of cAMP 
responses in HEL cells, we generated an HEL cell 
line that stably expressed the cAMP BRET sensor, 
CAMYEL (16).  Addition of prostaglandin E1 
(PGE1) elevates intracellular cAMP via Gs 
activation in these cells, while thrombin alone 
produces no cAMP response (Fig. 2A).  However, 
when thrombin was added to the cells following 
addition of PGE1, it elicited a large second peak of 
cAMP.  This response is transient, similar to the 
effect of S1P in RAW cells, and it diminishes 
within 10 minutes. We verified that this effect of 
thrombin was not mediated by the Gi or the 
Gq/Ca2+ pathways (data not shown) as reported 
previously (21,22).  When the α subunit of G13 in 
the HEL cells was knocked down by transfection 
with siRNA, the second peak response of cAMP 
triggered by thrombin was greatly reduced (Fig. 
2B).  Specific knock-down of AC7 in the HEL 
cells, produced a similar result.  Therefore, the 
synergistic regulation of cAMP by thrombin in 
this system also utilizes the G13 pathway and 
regulation of AC7 activity.   
The GPCRs that activate the Gs and G13 
pathways in HEL cells, EP receptor for PGE1 and 
PAR for thrombin, are both different from the β-
adrenergic and S1P2 receptors used in RAW cells.  
This is consistent with our previous assertion that 
the interactions between the Gs and the G13 
pathways occur downstream of receptor activation.  
In fact, when the intracellular cAMP concentration 
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was elevated by treatment with cholera toxin to 
directly activate the Gs protein and bypass 
activation of receptors, stimulation of the G13 
pathway was still able to induce a large increase in 
cAMP (Supplementary Fig. S2). 
 
BMDMs from AC7-/- mice are devoid of an S1P 
effect on cAMP stimulated by Gs-dependent 
pathways.  Bone marrow derived macrophage 
cells (BMDMs) offer an opportunity to examine 
regulation of AC7 by the G13 pathway in primary 
cells.  We were able to deliver the CAMYEL 
sensor into freshly isolated BMDM cells using 
retroviral infection for subsequent examination of 
cAMP responses in the cultured cells (see 
Experimental Procedures).  Like RAW cells, 
BMDMs elevate intracellular cAMP in response to 
stimulation with ISO.  Addition of S1P alone 
elicited a significant change in the concentration 
of intracellular cAMP (Supplementary Fig. S3), 
but induced a much larger second peak of cAMP 
when added after addition of ISO (Fig. 3B).  The 
synergy seen in BMDMs appears to be greater 
than that observed in RAW cells.  All of these 
response profiles are consistent with previous 
results when total cAMP was measured using a 
traditional enzyme-linked immunoassay (EIA) 
(16).   
To examine if the effect of S1P was mediated 
by Gi or the Gq/Ca2+ pathways, cells were treated 
respectively with either pertussis toxin to disable 
Gi or thapsigargin and EGTA to deplete 
intracellular and extracellular Ca2+.  Neither of 
these perturbations affected enhancement by S1P 
of the Gs-stimulated cAMP response in wild type 
BMDMs, as measured by the CAMYEL sensor 
(Fig. 3B).  The effectiveness of the chemical 
perturbations was confirmed by loss of modulation 
of Gs-induced cAMP by complement factor C5a or 
uridine 5’-diphosphate (UDP) (data not shown), 
which have been previously shown to couple 
through the Gi or Gq pathways, respectively (16).  
This result indicates that the effect of S1P in 
BMDMs is mediated by a G protein other than Gi 
or Gq. 
Mice with knockout of either Gα13 or AC7 
have been generated (24,25).  To determine the 
involvement of G13 and AC7 in the regulation of 
cAMP response by the S1P pathway in BMDMs, 
it would be ideal to obtain BMDMs from the 
knockout animals and examine their cAMP 
responses to stimulations with ISO and S1P.  
Unfortunately Gα13 knockout animals die during 
early embryogenesis (25).  While the majority of 
AC7 deficient animals are also embryonic lethal, 
~6% of AC7-/- mice do survive to adulthood (24) 
(L. I. Jiang, unpublished) and this leaky phenotype 
provided an opportunity to examine the role of 
AC7 in BMDM cells.  As shown in Figure 3C, 
AC7 deficient BMDMs failed to generate any 
second cAMP peak in response to S1P following 
stimulation with ISO.  BMDMs isolated from wild 
type or AC7+/- heterozygous litter mates displayed 
normal second peak responses to S1P.  Identical 
results were obtained with a different cohort of 
mice and when the cAMP responses were also 
measured with an EIA (Supplementary Fig. S4).   
Regulation of the Gs-stimulated cAMP 
responses by the Gi and Gq/Ca2+ pathways were 
also examined in the AC7 deficient BMDMs.  
Addition of C5a or UDP following that of ISO 
induced 2nd cAMP peak responses in wild type and 
AC7+/- heterozygous BMDMs (Fig. 3D-E).  
However, these 2nd peak responses were all 
abolished in AC7 deficient BMDMs.  This result 
suggests that AC7 is the key isozyme for 
integration of multiple signals that regulate cAMP  
in BMDMs.  
Despite the complete lack of second peak 
responses induced by the non-Gs pathways, AC7-/- 
BMDMs displayed only slightly reduced cAMP 
responses to stimulation with low doses of ISO 
alone (Fig. 3C-E).  When a high dose of ISO (160 
nM) was used to stimulate the cells, the cAMP 
response in AC7-/- BMDMs was reduced to about 
50% of that observed in wild type cells (Fig. 3F).  
Again, residual activity is presumably due to the 
presence of other AC isoforms in the BMDMs.  
However, integration of inputs from the non-Gs 
pathways appears to depend totally on AC7. 
 
Exogenous expression of AC7 is sufficient to 
recapitulate the S1P/G13 effect on intracellular 
cAMP responses.  Reduction of AC7 expression in 
the hematopoietic cell lines described above 
largely attenuated the effect of the G13 pathway on 
cAMP responses stimulated by Gs.  One possible 
explanation is that AC7 is the major isoform of 
adenylyl cyclase in those cells and therefore the 
fortuitous recipient for the signal integration 
measured.  To further address this issue, we 
attempted to recapitulate this regulation in HEK 
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293 cells by exogenous expression of specific AC 
isoforms. 
Wild type HEK 293 cells increase cAMP in 
response to stimulation with ISO but not with S1P.  
In addition, application of S1P simultaneously 
with or sequentially after addition of ISO did not 
produce any enhancement of the ISO response 
alone (Fig. 4A).  Expression of AC7 in these cells 
caused a small rise of intracellular cAMP 
concentration to stimulation with S1P alone (Fig. 
4C).  This response to S1P alone is Gs-dependent 
because knockdown of Gs abolished this response 
(data not shown).  When these cells with 
exogenous expression of AC7 were challenged 
with S1P following ISO addition, a second peak of 
response was observed (Fig. 4C).  The response to 
S1P in the presence of ISO was much larger than 
that observed with S1P alone, thus emulating the 
synergism seen in the hematopoietic cells.  HEK 
293 cells express several isoforms of ACs 
endogenously which contribute to the response to 
ISO alone.  Exogenous expression of AC7 in these 
cells contributed little to no increase in the 
response of cAMP to ISO alone; this suggests that 
the synergistic action of S1P on the actual activity 
of AC7 could be much larger than observed in 
context of the total activity measured in the cells. 
We subsequently knocked down Gα13 and 
AC7 in HEK 293 cells carrying stable expression 
of AC7 using an RNAi approach.  As shown in 
Figure 4F, knockdown of either Gα13 or AC7 
reduced the enhanced cAMP response caused by 
S1P following the addition of ISO.  The cAMP 
response to S1P alone in those cells was also 
decreased (Fig. 4E), suggesting that the S1P 
response alone is due to synergy with some tonic 
stimulation of AC7 by a Gs dependent mechanism.  
Taken together, these data suggest that exogenous 
expression of AC7 in HEK 293 cells is sufficient 
to recapitulate the S1P/G13 effect on Gs-stimulated 
cAMP responses.  
Type VII adenylyl cyclase belongs to the same 
subclass of ACs as AC2 (7,11).  These two 
isoforms show over 70% sequence identity in the 
catalytic domains and are similarly regulated by 
Gβγ based on in vitro assays (26,27).  As a control 
we chose to express AC2 in HEK 293 cells for 
comparison of responses with those seen by 
expression of AC7.  Cells with exogenous 
expression of AC2 also gave a small rise of 
intracellular cAMP when stimulated with S1P 
alone (Fig. 4D).  This response is Gs-dependent 
and partially sensitive to pertussis toxin treatment 
(data not shown). When S1P was applied 
following addition of ISO, a 2nd peak response was 
observed (Fig. 4D).  However, in contrast to 
responses seen with AC7,  this second response in 
the AC2 overexpressing cells was similar to 
stimulation seen with S1P alone, an additive 
response.  
The fact that only overexpression of AC7, but 
not AC2, recapitulated regulation on cAMP by the 
S1P/G13 pathway indicates that these two ACs can 
provide highly differential responses in cells.  This 
contrasts with past characterization which showed 
only similar regulatory properties for members of 
this AC subclass. 
 
G13 regulation of AC7 activity is mediated by its α 
subunit.  The type II subclass of ACs, which 
includes AC2, AC4 and AC7, can be regulated by 
Gβγ subunits.  Once activated by Gs, their 
activities can be further enhanced by direct 
binding of βγ subunits from the Gi pathway.  
Although βγ subunits derived from activation of 
G12/13 have not been shown to have any 
downstream function, they could affect AC 
activities as do the βγ subunits from Gi.  However, 
the magnitude of the synergy and its specificity for 
AC7 argue against this possibility.  
To test this directly, we overexpressed 
functional domains that can specifically block the 
actions of Gβγ or the α subunit of G13.  The PH 
domain of Grk2 (G protein receptor kinase) has 
been shown to bind Gβγ and block its function 
(28).  When this Grk-PH domain was expressed in 
293T cells that over expressed exogenous AC2, 
the cAMP response to S1P was reduced (Fig. 5B). 
However, the synergistic response of S1P in cells 
overexpressing AC7 was not affected by this PH 
domain (Fig. 5A). 
In contrast, the response to S1P in cells 
expressing AC7 was largely attenuated by 
overexpression of the rgRGS domain of 
p115RhoGEF (Fig. 5A).  This domain can block 
the effects of the G12/13 family by binding 
specifically to α subunits of G12 and G13 (29).  
Expression of the rgRGS domain in cells 
expressing AC2 appeared to cause elevation of 
basal cAMP levels, but did not affect the 
stimulation of cAMP by S1P in the presence of 
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ISO.  These data are consistent with the notion that 
in cells expressing AC2, stimulation by S1P is 
mediated by the Gi pathway via direct interaction 
of its βγ subunits with AC2.  In the case of AC7, 
modulation by S1P is mediated by the α subunit of 
G13 rather than its βγ subunits.  This is similar to 
other downstream effects of this G protein that 
have been sufficiently characterized (30).    
Similar experiments have been attempted in 
RAW 264.7 cells, but apparent lower expression 
of the domains curtailed any significant effects, 
including attenuation of known responses such as 
the Gi mediated stimulation of Ca2+ by C5a 
through its βγ subunits.   
 
Overexpression of wild type Gα12 rescues 
knockdown of Gα13.  The Gα12 and Gα13 proteins 
belong to the same subclass of heterotrimeric G 
proteins and share some common downstream 
effectors (30).  Is the effect of the S1P pathway on 
cAMP synthesis specifically mediated by G13 or 
also downstream of G12? Attempts to knockdown 
Gα12 by RNAi in RAW cells produced only partial 
reduction of the protein and did not show any 
effect on the S1P regulation of cAMP stimulated 
by Gs (data not shown).  It is possible that the 
knockdown was not adequate, that the S1P2 
receptor preferentially couples to Gα13 in RAW 
cells, that Gα12 does not couple to AC7, or that the 
endogenous expression of Gα12 is insufficient to 
provide effective coupling in this system.  We 
resorted to an alternative approach by testing 
whether overexpression of wild type Gα12 was 
able to rescue the phenotypes caused by 
knockdown of Gα13.   
A RAW cell line that stably carries inducible 
expression of Gα12 was established using infection 
with lentivirus (19).  Overexpression of Gα12 was 
induced in this cell line by addition of doxycyclin 
in the culture medium.  Knockdown of Gα13 was 
achieved by transient transfection of siRNA.  As 
shown in Figure 6A, knockdown of Gα13 reduced 
the amount of Gα13 protein to ~30% of the control 
while overexpression of Gα12 (+Dox) increased 
the α subunit about 5 fold over the endogenous 
level.  Overexpression of wild type Gα12 appeared 
to slightly reduce the cAMP response to ISO alone 
but retained the effect of S1P (2nd cAMP peak) 
(Fig. 6B).  Knockdown of Gα13 greatly reduced 
the synergistic effect of S1P (2nd cAMP peak), as 
reported before (16).  When overexpression of 
Gα12 was induced in the Gα13 knockdown cells, 
the enhancement of cAMP by S1P was largely 
restored.  This result indicates that the G12 
pathway is capable of regulating Gs-stimulated 
cAMP responses and shares this novel regulatory 
activity with G13. 
 
Overexpression of constitutively active forms of 
the Gα12 and Gα13 attenuates the effect of S1P on 
cAMP responses in RAW cells.  The effect of S1P 
on intracellular cAMP stimulated by Gs clearly 
requires activation of the G13 protein.  Since this 
regulation is mediated by the α subunit of G13, we 
tested if a constitutively active mutant of Gα13, 
Gα13Q226L (Gα13QL), would result in 
constitutive sensitization of AC7 to Gs stimulation.  
The Gα13QL mutant lacks GTPase activity and has 
been shown to cause constitutive activation of 
RhoA, a major downstream effector of the G13 
pathway (31,32).  This effect of the activated α 
subunit on RhoA-GTP is also observed in RAW 
cells (Fig. 7B).  If this mutant form of Gα13 had a 
similar effect on cAMP responses in RAW cells, 
we would expect a greatly enhanced cAMP 
response to ISO stimulation alone in cells 
overexpressing the Gα13QL mutant protein.  In 
contrast, we found that overexpression of 
constitutively active Gα13QL did not affect the 
cAMP response to ISO (Fig. 7C) alone.  
Surprisingly, the synergistic 2nd peak induced by 
S1P in the presence of ISO was diminished by 
overexpression of Gα13QL.  Thus, this 
constitutively active protein gives a dominant 
negative phenotype with respect to cAMP 
regulation.  Clearly, regulation of RhoA and of 
cAMP responses by the G12/13 pathway have 
distinct mechanisms.  Overexpression of 
constitutively active Gα12QL produced identical 
results (Fig. 7C), consistent with the notion that 
Gα12 and Gα13 proteins are interchangeable.  
Overexpression of Gα12QL or Gα13QL did not 
affect Ca2+ responses to various ligands that use Gi 
and Gq pathways (data not shown).  More 
importantly, modulation of cAMP responses by 
ligands that stimulate the Gi or Gq pathways, C5a 
and UDP respectively, remained unchanged (Fig. 
7D,E).  This result argues that overexpression of 
Gα12/13QL is unlikely to regulate the activity of Gs; 
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rather it acts to attenuate the G13 pathway that 
converges on AC7. 
 
DISCUSSION 
 
Precise regulation of intracellular cAMP is 
crucial for this ubiquitous second messenger to 
control a wide variety of cellular functions, 
including cell proliferation and differentiation (2), 
cell metabolism (2), memory formation (5), 
cardiac contractility (4), and immune responses 
(1,3).  It has been shown that expression of 
specific isoforms, subcellular localization, and 
differential regulation of ACs greatly contribute to 
the diverse and tissue specific regulation of cAMP 
(33-37).  Here we report a novel regulatory 
pathway for control of cAMP synthesis in three 
hematopoietic cell lines.  A G12/13 pathway can 
enhance Gs-dependent increases in cAMP in these 
cells and this synergy is mediated by a specific AC 
isoform, AC7.   
AC7 has been grouped together with AC2 and 
AC4 as a subfamily of AC isozymes based on 
sequence similarities and their regulation by G 
protein βγ subunits (11,26,27,38).  However, our 
results suggest that AC7, but not AC2, is a specific 
AC isoform required for regulation of cAMP by 
the G12/13 pathway.  While HEL cells do not 
express AC2, RAW cells and BMDMs do express 
the isozyme.  In the case of RAW cells, 
knockdown of AC2 mRNA to a similar extent as 
that of AC7 did not affect regulation of cAMP by 
the S1P/G13 pathway.  In contrast, BMDMs 
deficient in AC7 were unable to respond to the 
S1P/G13 pathway in their cAMP response.  More 
importantly, exogenous expression of AC7, but 
not AC2, in HEK 293 cells recapitulated 
regulation of cAMP responses by the G12/13 
pathway.  These data clearly distinguish selective 
actions of AC7 vs. AC2.  None of the cell lines 
examined in this study expresses AC4 and its 
sensitivity to the S1P/G13 pathway remains to be 
determined.  
How does the G12/13 pathway increase 
intracellular cAMP? It has been shown previously 
that this regulation occurs via increased rates of 
cAMP synthesis rather than decreased rates of 
degradation (16).  Several pieces of evidence 
indicate that the most likely mechanism involves 
direct action of the G12/13 pathway on the AC itself.   
First, it is clear that this regulation occurs 
downstream of the receptors, since this interaction 
exists between a variety of ligands that stimulate 
unique receptors coupled to the G12/13 or Gs 
pathways in several cell lines.  Second, direct 
activation of Gs via modification with cholera 
toxin is a sufficient basis for enhancement of 
cAMP responses by the G12/13 pathway 
(Supplementary Fig. S2).  Third, this regulation 
relies on a specific isoform of AC, AC7.  Fourth, 
overexpression of the constitutively active 
Gα12/13QL mutants specifically disrupts 
modulation of cAMP responses from the G12/13 
pathway but not that from the Gi or Gq/Ca2+ 
pathways.  If indeed the G12/13 pathway directly 
regulates AC7 activity, a prediction is that direct 
activation of the AC enzyme might allow 
synergistic activation with the G12/13 pathway.  We 
attempted to test this hypothesis by directly 
activating ACs with forskolin. Addition of 
forskolin to HEL cells or to 293 cells expressing 
AC7 elevated their intracellular cAMP, but 
activation of the G12/13 pathway with thrombin or 
S1P failed to induce a further enhanced cAMP 
response (data not shown).  There are minimally 
two reasons that such an experiment may not work.  
First, several ACs are expressed in the cells 
assayed here and they have different sensitivities 
to forskolin.  If AC7 is less sensitive to forskolin 
than other ACs as has been reported for AC2 (39), 
any synergism may get lost in the large signal 
from other ACs in the cells.  Second, even though 
an AC can be activated by forskolin, the activation 
state of the protein appears to have a different 
conformation than when it is activated by Gs (40-
42).  Therefore, coupled regulation of the ACs 
may be different with the two forms of activation.  
For example, the activity of AC2 in vitro can be 
enhanced by Gβγ when AC2 is activated by Gs, 
but not if it is activated by forskolin (R.  Taussig, 
personal communication).   
We have previously argued that the effect of 
G13 on cAMP responses is unlikely to be mediated 
by its βγ subunits even though Gs-stimulation of 
selected AC isoforms can be enhanced by Gβγ 
(16).  In this study, we provide convincing 
evidence that regulation of AC7 activity by the 
G12/13 pathway is indeed mediated by the α 
subunits of this class of G proteins.  The direct 
experiment was to specifically block the function 
of the α or βγ subunits of G13 by overexpression of 
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the p115-rgRGS or Grk-PH domains, respectively.  
Differential results were obtained in cells 
expressing AC2 or AC7.  Blocking the function of 
the Gα13 subunit with overexpression of the p115-
rgRGS domain specifically blunted the effect of 
S1P on the Gs stimulated cAMP response in cells 
expressing AC7.  In contrast, sequestration of Gβγ 
with the Grk-PH domain reduced the effect of S1P 
only in cells expressing AC2. 
Additional results are consistent with this 
conclusion.  First, the activities of both AC2 and 
AC7 can be modulated by Gβγ but the regulation 
by G13 is specifically mediated by AC7, not AC2.  
Second, overexpression of constitutively active 
Gα12QL or Gα13QL negates regulation of cAMP 
by the G12/13 pathway but did not affect other G 
protein pathways.  Taken together, the 
heterotrimeric G12/13 proteins must exert this 
regulation of cAMP via their α subunits. 
A major downstream effector of the G12/13 
pathway is the RhoA GTPase (31,43), which can 
be mediated by interaction of activated α subunits 
with a family of RGS-RhoGEFs (44).  Here, we 
have identified AC7 as a novel downstream 
effector of the G12/13 pathway, either by direct 
interaction with the Gα12/13 proteins or via 
unknown intermediates.  Yet, the engagement of 
the activated α subunits with these two effectors 
appears to differ.  While regulation of both 
effectors in vivo by extracellular stimuli apparently 
requires activation of the G protein and both 
responses are transient, long term responses differ.  
In contrast to the long-term activation of RhoA by 
overexpression of activated Gα12QL or Gα13QL, 
effects on AC activity are blocked by expression 
of the activated subunits.  This may suggest that 
the turn off mechanisms of these two responses are 
different.  In the case of RhoA activation, the turn 
off mechanism lies upstream or at the level of G 
protein activation, possibly involving receptor 
desensitization.  Due to the absence of an efficient 
turn off mechanism downstream, expression of a 
constitutively active G12/13 α subunit leads to 
sustained RhoA activation.  However, the cAMP 
response was greatly attenuated by expression of 
the activated G protein α subunits.  Thus suggests 
a potent turn off mechanism downstream of the 
receptors and G protein.  This turn off mechanism 
is unlikely to be mediated by the primary output, 
cAMP, as the effect of S1P can be observed at 
various times after the second messenger has been 
elevated in cells (16).  Further, the transient nature 
of the S1P effect is also observed in the absence of 
cAMP; that is, the ability of the G12/13 pathway to 
enhance cAMP synthesis invoked by the Gs 
pathway is lost over 5 minutes if S1P is added to 
cells first followed by ISO at various delayed 
times (Supplementary Fig. S5). 
At this time, precise mechanisms for either 
stimulation of AC7 by the G12/13 pathway or 
desensitization of the regulation are unknown.  
Either may be mediated by direct interaction of the 
G protein α subunits with the cyclase or involve 
yet to be identified intermediate proteins.  
Attempts to examine direct interactions between 
Gα13 and AC7 by co-immunoprecipitation and 
direct regulation of AC7 by Gα13 using membrane 
assays have not yielded any positive result so far.  
Determining if an additional player is involved in 
this interaction and identification of such a protein 
may hold the key to understanding the molecular 
mechanism of AC7 regulation by the G12/13 
pathway.  Several studies have revealed various 
proteins that interact with the α subunit of the 
G12/13 proteins (45-48).  While we have shown 
previously that RhoA activity is not required for 
the effect on cAMP regulation (16), other 
interacting proteins could be potential candidates 
for mediation if required. 
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FIGURE LEGENDS  
 
Figure 1.  Specific knockdown of AC isoforms in RAW 264.7 cells identifies AC7 as a key regulator for 
integration of the S1P/G13 effect on cAMP.  Each AC isoform was knocked down individually in RAW 
cells that stably express the CAMYEL sensor either using retrovirus carrying shRNA (for AC2 and AC3) 
or by transient transfection of siRNA (for AC7 and AC9).  Control cells carrying stable expression of 
non-specific shRNA or transient expression of non-specific siRNA were generated in parallel.  Matching 
control cells were used for qRT-PCR analysis.  cAMP responses in both control cells were similar  and 
the former is shown.  (A). The effectiveness and isoform specificity of knockdowns was determined by 
qRT-PCR.  (B). Cells treated for knockdowns as indicated were stimulated with 16 nM ISO at time 0, 
followed by addition of 10 nM S1P at 120 seconds.  Intracellular cAMP was measured by BRET assay 
using CAMYEL.  Error bars for the control response represent the standard deviation of results from 3 
independent experiments.  Errors were similar for the other conditions but left out for clarity. 
 
Figure 2.  The effect of thrombin on cAMP responses in HEL cells is also mediated by Gα13 and AC7.  
(A). An HEL cell line that stably expresses the CAMYEL sensor was established through retroviral 
infection and selection.  The cells were treated with 100 nM PGE1 or 1U/ml thrombin at time 0, or with 
100 nM PGE1 at time 0 followed by 1 U/ml thrombin at 120 seconds.  Intracellular cAMP was measured 
using the BRET assay.  (B). HEL cells carrying the CAMYEL sensor were transiently transfected with 
control oligos or siRNA oligos targeting Gα13 (a single oligo designated as –A) or AC7 (a pool of 4 
oligos designated as –P).  Cells were assayed for cAMP responses to sequential addition of 100 nM PGE1 
at time 0 followed by 1 U/ml thrombin at 120 seconds as indicated.  Knockdown of Gα13 was 64% as 
assessed by western blot and knockdown of AC7 was 53% as assessed by qRT-PCR.  Error bars represent 
the standard deviation of results from 3 independent experiments. 
 
Figure 3.  Absence of an S1P effect on cAMP responses in AC7-/- BMDMs.  (A). BMDM cells were 
isolated from 6-week old female mice of the same litter.  The genotype of the BMDMs was determined 
by PCR.  (B-F). Freshly isolated BMDMs were infected with retrovirus carrying the CAMYEL sensor.  
cAMP responses were measured using the BRET assay.  (B). Wild type BMDMs were treated with buffer 
alone, 100 ng/ml pertussis toxin (PTx) for 20 hours, or 10 µM thapsigargin and 2 mM EGTA (TG/EGTA) 
for 2 minutes as indicated and stimulated with sequential addition of 4 nM ISO at time 0 followed by 4 
nM S1P at 120 seconds.  (C-E). Three genotypes of BMDM cells were treated with sequential addition of 
4 nM ISO at time 0 followed by 4 nM S1P (C), 50 nM C5a (D), or 500 nM UDP (E) at 120 seconds as 
indicated by arrows.  (F). Three genotypes of BMDM cells were stimulated with 160 nM ISO at time 0.  
Reprsentative error bars for selected traces are the standard deviation of results from 3 experiments. 
 
Figure 4.  Overexpression of AC7 but not AC2 in HEK 293 cells recapitulates the S1P/G13 effect on 
cAMP response.  HEK 293 cells that stably express the CAMYEL sensor were established through 
retroviral infection and selection.  (A). Intracellular cAMP was measured in these cells using the BRET 
assay.  The cells were stimulated with 50 nM S1P at time 0 (gray trace) or with 4 nM ISO at time 0 
followed by 50 nM S1P at 120 seconds (black trace).  (B-D). HEK 293 cells carrying CAMYEL sensor 
were transiently transfected with cDNA encoding epitope-tagged AC2 or AC7.  (B). Expression of the 
proteins was verified by western blot using antibodies against the specific epitopes.  (C-D). cAMP 
responses were measured when the cells were stimulated with 50 nM S1P at 120 seconds (gray trace) or 
with 4 nM ISO at time 0 followed by 50 nM S1P at 120 seconds (black trace). The dashed trace 
represents the predicted sum of responses to ISO alone (not shown) and S1P alone.  (E-F). HEK 293 cells 
that stably express both the CAMYEL sensor and AC7 were established through retroviral infection and 
selection.  The cells were then transiently transfected with control siRNA oligos or siRNA oligos 
targeting Gα13 (a single oligo designated as –A) or AC7 (a pool of 4 oligos designated as –P).  Knock 
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down of either protein resulted in reduced cAMP responses to stimulation with 50 nM S1P alone at time 0 
(E) or at 120 seconds following addition of 10 nM ISO at time 0 (F) as indicated.  Error bars represent the 
standard deviation of results from 3 experiments. 
 
Figure 5.  Regulation of AC7 is mediated by the α subunit of G13. 293T cells expressing the CAMYEL 
sensor and either AC7 (A) or AC2 (B) were co-transfected with control DNA, or DNA encoding epitope-
tagged Grk-PH or p115-rgRGS domains.  Expression of the proteins was verified by western blot using 
antibodies against the specific epitopes (C).  48 hours post transfection, cells were stimulated with 4 nM 
ISO at time 0 followed by 5 nM S1P at 120 seconds; cAMP responses were measured using the BRET 
assay.  Error bars represent the standard deviation of results from 3 experiments. 
 
Figure 6.  Overexpression of Gα12 rescues the cAMP phenotype caused by knockdown of Gα13 in RAW 
264.7 cells.  RAW cells that stably express the CAMYEL sensor were infected with lentivirus carrying 
Gα12 cDNA under an inducible promoter.  The cells were first transiently transfected with control siRNA 
or siRNA oligos (-G) targeting Gα13.  24 hours post transfection the cells were split onto 96-well plate, 
and cultured overnight either in the absence or presence of 0.5 µg/ml doxycyclin as indicated.  (A). 
Inducible expression of Gα12 and knockdown of Gα13 were examined by western blot using antibodies 
specific to Gα12 or Gα13.  (B). The cells were challenged with 16 nM ISO at time 0 followed by 10 nM 
S1P at 120 seconds and cAMP was measured using the BRET assay.  Error bars represent the standard 
deviation of results from 3 experiments.   
 
Figure 7.  Expression of the constitutively active mutants of Gα12 or Gα13 diminish the S1P effect on Gs-
stimulated cAMP in RAW 264.7 cells.  RAW cells that stably express the CAMYEL sensor were infected 
with lentivirus carrying Gα12QL or Gα13QL cDNA under an inducible promoter.  (A). Inducible 
expression of Gα12QL and Gα13QL proteins was achieved by addition of 0.5 µg/ml doxycyclin in cell 
culture media for 1 day.  Protein expression was determined by western blot using specific antibodies.  
(B). The effectiveness of G12QL or G13QL proteins was verified by assessment of RhoA activation.  Cells 
were stimulated with 1 µM S1P.  Reactions were stopped at 1 minute and cells were lysed and assayed for 
activated RhoA using the G-LISA kit (see Materials and Methods).  (C). Treated cells were stimulated 
with 16 nM ISO at time 0 followed by 10 nM S1P at 120 seconds.  (D-E). Overexpression of G13QL did 
not affect regulation of cAMP responses mediated through the Gi or Gq/Ca2+ pathways.   Treated cells as 
indicated were stimulated with 16 nM ISO at time 0 and either 100 nM C5a (D) or 500 nM UDP (E) at 
120 seconds, respective ligands for activation of Gi or Gq/Ca2+ pathways.  Intracellular cAMP was 
measured using the BRET assay.  Error bars represent the standard deviation of results from 3 
experiments. 
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on June 23, 2008 
w
w
w
.jbc.org
D
ow
nloaded from
 
 14
 
Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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Figure 7. 
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